Arcus Biosciences, Inc. (NYSE:RCUS) Receives $30.20 Consensus PT from Analysts
Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has […]
1 Apr 12:40 · The Markets Daily